Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population

Gene

Volumn 487, Issue 1, 2011, Pages 88-95

  Gupta, Nidhi ^a   Binukumar, B K ^a   Singh, Surjit ^a   Sunkaria, Aditya ^a   Kandimalla, Ramesh ^a   Bhansali, Anil ^a   Gill, Kiran Dip ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

AREase activity; Haplotypes; Linkage disequilibrium; PON1 polymorphisms; PONase activity; Type 2 diabetes mellitus

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LIPID; OLIGONUCLEOTIDE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HUMAN; INDIAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 80052313274     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.07.011     Document Type: Article

References (34)

1. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1812-1818.
2. Agachan B., Yilmaz H., Karaali Z., Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem. Funct. 2004, 22:163-168.
3. Altuner D., Suzen S.H., Ates I., Koc G.V., Aral Y., et al. Are PON1 Q/R 192 and M/L 55 polymorphisms risk factors for diabetes complications in Turkish population?. Clin. Biochem. 2011, 44:372-376.
4. Aviram M., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000, 101:2510-2517.
5. Berkowitz G.S., et al. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ. Health Perspect. 2004, 112:388-391.
6. Campo S., et al. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp. Gerontol. 2004, 39:1089-1094.
7. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu. Rev. Med. 2003, 54:371-392.
8. Daly A.K., Steen V.M., Fairbrother K.S., Idle J.R. CYP2D6 multiallelism. Methods Enzymol. 1996, 272:199-210.
9. Ergun M.A., Yurtcu E., Demirci H., Ilhan M.N., Barkar V., et al. PON1 55 and 192 gene polymorphisms in type 2 diabetes mellitus patients in a Turkish population. Biochem. Genet. 2011, 49:1-8.
10. Flekac M., Skrha J., Zidkova K., Lacinova Z., Hilgertova J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol. Res. 2008, 57:717-726.
11. Furlong C.E., et al. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genomics 2006, 16:183-190.
12. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 1991, 19:100-106.
13. Gordon D., Finch S.J., Nothnagel M., Ott J. Power and sample size calculations for case-control genetic association tests when errors are present: application to single nucleotide polymorphisms. Hum. Hered. 2002, 54:22-33.
14. Gordon D., Levenstien M.A., Finch S.J., Ott J. Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies. Pac. Symp. Biocomput. 2003, 490-501.
15. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998, 339:229-234.
16. Hegele R.A., Brunt J.H., Connelly P.W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 1995, 15:89-95.
17. Humbert R., et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 1993, 3:73-76.
18. Inoue M., et al. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000, 49:1400-1405.
19. Juretic D., et al. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus. Acta Pharm. 2006, 56:59-68.
20. Kalmar T., et al. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes Metab. 2005, 31:574-580.
21. Khersonsky O., Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44:6371-6382.
22. La Du B.N. Human serum paraoxonase/arylesterase. Pharmacogenetics of Drug metabolism 1992, 51-91. Pergamon Press, New York USA. W. Kalow (Ed.).
23. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991, 286:152-154.
24. Mackness M.I., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991, 86:193-199.
25. Mackness B., et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998, 139:341-349.
26. Nathan D.M., Meigs J., Singer D.E. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is or is it?. Lancet 1997, 350(Suppl. 1):SI4-SI9.
27. Richter R.J., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9:745-753.
28. Richter R.J., Jarvik G.P., Furlong C.E. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ. Cardiovasc. Genet. 2008, 1:147-152.
29. Richter R.J., Jarvik G.P., Furlong C.E. Paraoxonase 1 status as a risk factor for disease or exposure. Adv. Exp. Med. Biol. 2010, 660:29-35.
30. Rompler H., et al. Multiplex amplification of ancient DNA. Nat. Protoc. 2006, 1:720-728.
31. Ruiz J., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995, 346:869-872.
32. Sakai T., Matsuura B., Onji M. Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern. Med. 1998, 37:581-584.
33. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989, 320:915-924.
34. Tomas M., Latorre G., Senti M., Marrugat J. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev. Esp. Cardiol. 2004, 57:557-569.